ClinConnect ClinConnect Logo
Search / Trial NCT06541496

Influence of Fitzpatrick Skin Phototype and Body Mass Index on Non-invasive Optoacoustic Imaging

Launched by UNIVERSITY OF ERLANGEN-NÜRNBERG MEDICAL SCHOOL · Aug 5, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how skin type and body weight affect the way our muscles get oxygen and blood flow during exercise. The researchers are using a new imaging technology called Multispectral Optoacoustic Tomography (MSOT) to see how different skin tones and body mass index (BMI) change the way our muscles respond when blood flow is restricted and during a simple toe-raising exercise. They will recruit healthy volunteers aged 65 to 74 with various skin tones and BMI to participate in the study.

To join the trial, participants must give their consent and be in generally good health. However, individuals who are pregnant, have diabetes, kidney problems, peripheral artery disease, muscle diseases, tattoos in the scanning area, or who do not provide consent will not be eligible. Participants can expect to undergo some exercises and then have scans done on their arms and legs to measure how well their muscles are getting blood and oxygen during the activities. This study will help us better understand how different factors influence muscle health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Signed informed consent
  • Exclusion Criteria:
  • Pregnancy
  • diagnosed diabetes
  • diagnosed renal insufficiency
  • diagnosed Peripheral arterial disease
  • diagnosed muscle associated disease
  • tattoos in scan area
  • missing consent form

About University Of Erlangen Nürnberg Medical School

The University of Erlangen-Nürnberg Medical School is a prestigious institution dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. Renowned for its interdisciplinary approach, the medical school fosters collaboration among experts in various fields, enabling the development of cutting-edge therapies and treatment protocols. With a commitment to ethical standards and patient safety, the institution actively contributes to the global medical community by conducting rigorous clinical studies aimed at enhancing the understanding and management of diverse health conditions.

Locations

Munich, Bavaria, Germany

Patients applied

0 patients applied

Trial Officials

Ferdinand Knieling, PD Dr. med. habil.

Principal Investigator

Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported